Guangdong Hybribio Biotech Co.,Ltd.

300639

CNE100002N51

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6.2 ^CNY	+2.31%		+1.47%	-33.62%

Apr. 26	Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	Guangdong Hybribio Biotech Co.,Ltd. Proposes Final Dividend for the Year 2023	CI

Guangdong Hybribio Biotech Co.,Ltd. Approves Cash Dividend for 2022

May 08, 2023 at 03:33 pm EDT

Guangdong Hybribio Biotech Co.,Ltd. at its Annual General Meeting of 2022 held on 05 May 2023 approved Cash dividend/10 shares (tax included) of CNY 3.50000000 for 2022.

Latest news about Guangdong Hybribio Biotech Co.,Ltd.

Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Guangdong Hybribio Biotech Co.,Ltd. Proposes Final Dividend for the Year 2023	Apr. 23	CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 23	CI
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on February 6, 2024.	Apr. 01	CI
Guangdong Hybribio Biotech, Subsidiary Get Patent from Brazil for Isolation Method	Mar. 22	MT
Hybribio Biotech's Unit Secures Registration Certificate for Nucleic Acid Analysis System	Feb. 23	MT
Guangdong Hybribio Biotech Co.,Ltd. announces an Equity Buyback for CNY 60 million worth of its shares.	Feb. 05	CI
Guangdong Hybribio Biotech Co.,Ltd. authorizes a Buyback Plan.	Feb. 04	CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Two Guangdong Hybribio Biotech Units Get Licenses from Drug Regulator	23-09-04	MT
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Guangdong Hybribio Biotech Registers Gene Testing Kit	23-08-18	MT
Hybribio Showcases Cutting-Edge Cervical Cancer HPV Diagnostic Solutions At ADLM 2023	23-07-31	CI
Hybribio Biotech Appoints Chief Medical Officer	23-06-27	MT
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on October 26, 2022.	23-05-24	CI
Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback announced on October 26, 2022 has closed with 5,937,000 shares, representing 0.91% for CNY 100 million.	23-05-22	CI
Guangdong Hybribio Biotech Co.,Ltd. Announces Cash Dividend on A Shares for Year 2022, Payable on May 22, 2023	23-05-12	CI
Guangdong Hybribio Biotech Co.,Ltd. Approves Cash Dividend for 2022	23-05-08	CI
Hybribio Biotech Patents HPV Gel in Indonesia	23-05-04	MT
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-24	CI
Guangdong Hybribio Biotech Co.,Ltd. Proposes Final Cash Dividend for the Year 2022	23-04-17	CI
Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-14	CI
Tranche Update on Guangdong Hybribio Biotech Co.,Ltd.'s Equity Buyback Plan announced on October 26, 2022.	23-04-02	CI
Guangdong Hybribio Biotech Registers Gene Testing Device	23-03-16	MT
Hybribio Biotech Patents Chloroquine Phosphate Gel in Europe	23-02-13	MT

Chart Guangdong Hybribio Biotech Co.,Ltd.

Duration

Period

Chart Guangdong Hybribio Biotech Co.,Ltd.

More charts

Guangdong Hybribio Biotech Co Ltd is a company mainly engaged in production and sales of vitro diagnostic reagents. The Company operates two segments. The In Vitro Diagnostic Reagents and Supporting Equipment segment operates the research, development and production of nucleic acid detection reagents and supporting equipment, such as cervical cancer detection series products, deafness susceptibility gene detection series products and reproductive health management series products. The products are used in hospital clinical testing, large-scale population screening and other areas. The Medical Testing Service segment is involved in providing medical testing services for medical institutions, and the testing programs cover genetic metabolic diseases, infectious diseases, molecular pathological testing and tumor examinations.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-26 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Guangdong Hybribio Biotech Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.2

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GUANGDONG HYBRIBIO BIOTECH CO.,LTD.	-33.62%	546M
BIOMÉRIEUX	+0.89%	12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-10.29%	7.61B
DIASORIN S.P.A.	+1.78%	5.41B
AUTOBIO DIAGNOSTICS CO., LTD.	-1.16%	4.51B
LANTHEUS HOLDINGS, INC.	+5.74%	4.49B
10X GENOMICS, INC.	-50.70%	3.29B
ANDON HEALTH CO., LTD.	+12.21%	2.73B
VITROLIFE AB	-16.13%	2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-11.50%	1.73B

Diagnostic & Testing Substances